Choroidal Melanoma News and Research

RSS

The choroid in the eye is part of the uveal tract. This is made up of the colored iris, the ciliary body, and the choroid. All are rich in melanocytes, the specialized cells that produce melanin. This pigment is a dark-colored, light-absorbing particle.

As AI eye exams prove their worth, lessons for future tech emerge

Christian Espinoza, director of a Southern California drug-treatment provider, recently began employing a powerful new assistant: an artificial intelligence algorithm that can perform eye exams with pictures taken by a retinal camera. It makes quick diagnoses, without a doctor present.

27 Mar 2024

Oraya awarded NIH grant to study how gold nanoparticles can enhance Wet AMD treatment

Oraya Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD).

6 Aug 2014

Aggressive surveillance questionable for eye melanoma recurrence

Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.

14 Jan 2013

UF Proton Therapy Institute successfully treats first eye cancer patient

The fixed beam room, or eyeline, at the University of Florida Proton Therapy Institute is up and running and radiation oncologist Robert Malyapa, M.D., Ph.D. completed treating the facility's first eye cancer patient this week.

10 Jun 2012

Researcher develops new plaque brachytherapy technique to treat eye cancer

Rare but devastating, eye cancer can strike anyone at any time and treating it often requires radiation that leaves half of all patients partially blind.But a new technique developed by Scott Oliver, MD, assistant professor at the University of Colorado School of Medicine, may change all that.

30 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

How does the immune system isolate and destroy intruders?

Dendritic cells are the body's "watchdogs". They recognize and then degrade pathogens, isolating characteristic fragments that are recognized by the immune system thus triggering targeted responses.

25 Jul 2006